Laetitia Comté
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laetitia Comté has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Vrijens
University of Liège, Liège, Belgium
2 shared publications - Eric Tousset
AARDEX Group, Visé, Belgium
1 shared publication John Urquhart
Pharmionic Systems Ltd
1 shared publicationPaul Gérard
University of Liège
1 shared publicationRichard A. Rode
Abbott Laboratories, Abbott Park, Ilinois, U.S.A.
1 shared publication- Stijn Vansteelandt
Department of Mathematics, Computer Science and Statistics, Ghent University
1 shared publication
Latest Publications
- 1 January 2011
- Published by International Press of Boston in Statistics and Its Interface
- Vol. 4 (4) , 511-520
Estimation of HIV treatment-efficacy by combining structural nested mean models with pharmacokinetic models of antiretroviral drug exposure
- 1 January 2011
- Published by International Press of Boston in Statistics and Its Interface
- Vol. 4 (4) , 511-520
Estimation of HIV treatment-efficacy by combining structural nested mean models with pharmacokinetic models of antiretroviral drug exposure
- 12 May 2007
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 34 (4) , 549-558
Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
Once-daily dosing almost invariably shows a slightly higher percentage of prescribed doses taken than does twice-daily dosing. Many pharmaceutical scientists, regulators, and prescribers have considered this finding to signify the therapeutic superiority of once-daily dosing. The therapeutically more relevant question, however, is not the percentage of prescribed doses taken but the comparative impact of missed doses on the pharmacologic effects of a drug under the two dosing regimens. A key point in this regard is that the pharmacokinetic equivalent of a single missed once-daily dose is 2–3 sequentially omitted twice-daily doses. Thus, an important parameter in comparing the two regimens is the probability of two or three twice-daily doses being sequentially omitted, versus the probability of missing a single once-daily dose. Our data indicate that the probability of sequential omission of 2–3 twice daily doses is half the probability of omission of a single once-daily dose. For that reason, a twice-daily regimen could prove to be superior to a once-daily regimen in maintaining drug concentrations within a therapeutically desirable range. A more important consideration, however, is to maintain not just the concentration of drug in plasma, but the drug’s therapeutic action. The duration of therapeutic drug action following a last-taken dose is not only drug-specific, but also, for some drug, dependent on the pharmacodynamic properties. Judging the comparative superiority of one dosing regimen over another requires knowledge of the drug’s duration action after a last-taken dose, plus knowledge of the comparative probabilities of the various patterns of dose omission. When applied to HIV protease inhibitors, a twice-daily regimen appears to be better than an once-daily regimen in maintaining therapeutically effective drug actions.
- 12 May 2007
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 34 (4) , 549-558
Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
Once-daily dosing almost invariably shows a slightly higher percentage of prescribed doses taken than does twice-daily dosing. Many pharmaceutical scientists, regulators, and prescribers have considered this finding to signify the therapeutic superiority of once-daily dosing. The therapeutically more relevant question, however, is not the percentage of prescribed doses taken but the comparative impact of missed doses on the pharmacologic effects of a drug under the two dosing regimens. A key point in this regard is that the pharmacokinetic equivalent of a single missed once-daily dose is 2–3 sequentially omitted twice-daily doses. Thus, an important parameter in comparing the two regimens is the probability of two or three twice-daily doses being sequentially omitted, versus the probability of missing a single once-daily dose. Our data indicate that the probability of sequential omission of 2–3 twice daily doses is half the probability of omission of a single once-daily dose. For that reason, a twice-daily regimen could prove to be superior to a once-daily regimen in maintaining drug concentrations within a therapeutically desirable range. A more important consideration, however, is to maintain not just the concentration of drug in plasma, but the drug’s therapeutic action. The duration of therapeutic drug action following a last-taken dose is not only drug-specific, but also, for some drug, dependent on the pharmacodynamic properties. Judging the comparative superiority of one dosing regimen over another requires knowledge of the drug’s duration action after a last-taken dose, plus knowledge of the comparative probabilities of the various patterns of dose omission. When applied to HIV protease inhibitors, a twice-daily regimen appears to be better than an once-daily regimen in maintaining therapeutically effective drug actions.